Literature DB >> 16156666

Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3.

Isao Matsuura1, Guannan Wang, Dongming He, Fang Liu.   

Abstract

Smad3 is phosphorylated by ERK MAP kinase upon EGF treatment. We have mapped the ERK phosphorylation sites to Ser 207, Ser 203, and Thr 178 in Smad3. We show that, upon EGF treatment, Smad3 is rapidly phosphorylated in these sites, peaking at approximately 15-30 min and that MEK1 inhibitors PD98059 and U0216 inhibit Smad3 phosphorylation induced by EGF. Ser 207 is the best ERK site in Smad3. Its phosphorylation shows the highest EGF induction in Smad3. It is also a very sensitive site to EGF treatment, significantly responding to low concentrations of EGF. These three sites are also phosphorylated by recombinant ERK2 in vitro. We have compared the kinetic parameters of Smad3 with those of ELK1 and MBP for ERK2. We further show that mutation of the ERK phosphorylation sites increases the ability of Smad3 to stimulate a Smad target gene, suggesting that ERK phosphorylation inhibits Smad3 activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156666     DOI: 10.1021/bi050560g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  55 in total

1.  Multiple decisive phosphorylation sites for the negative feedback regulation of SOS1 via ERK.

Authors:  Yuji Kamioka; Shuhei Yasuda; Yoshihisa Fujita; Kazuhiro Aoki; Michiyuki Matsuda
Journal:  J Biol Chem       Date:  2010-08-19       Impact factor: 5.157

2.  Role of Radiation-induced TGF-beta Signaling in Cancer Therapy.

Authors:  Horatiu C Dancea; Mohammed M Shareef; Mansoor M Ahmed
Journal:  Mol Cell Pharmacol       Date:  2009

3.  The prognostic significance of Smad3, Smad4, Smad3 phosphoisoform expression in esophageal squamous cell carcinoma.

Authors:  Soo Youn Cho; Sang Yun Ha; Song-Mei Huang; Jeong Hoon Kim; Myung Soo Kang; Hae-Yong Yoo; Hyeon-ho Kim; Cheol-Keun Park; Sung-Hee Um; Kyung-Hee Kim; Seok-Hyung Kim
Journal:  Med Oncol       Date:  2014-09-30       Impact factor: 3.064

4.  Clonorchis sinensis lysophospholipase inhibits TGF-β1-induced expression of pro-fibrogenic genes through attenuating the activations of Smad3, JNK2, and ERK1/2 in hepatic stellate cell line LX-2.

Authors:  Lina Zhou; Mei Shang; Mengchen Shi; Lu Zhao; Zhipeng Lin; Tingjin Chen; Yinjuan Wu; Zeli Tang; Hengchang Sun; Jinyun Yu; Yan Huang; Xinbing Yu
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

5.  Src is a major signaling component for CTGF induction by TGF-beta1 in osteoblasts.

Authors:  X Zhang; J A Arnott; S Rehman; W G Delong; A Sanjay; F F Safadi; S N Popoff
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

6.  Smad2 and PEA3 cooperatively regulate transcription of response gene to complement 32 in TGF-β-induced smooth muscle cell differentiation of neural crest cells.

Authors:  Wen-Yan Huang; Weibing Xie; Xia Guo; Fengmin Li; Pedro A Jose; Shi-You Chen
Journal:  Am J Physiol Cell Physiol       Date:  2011-05-25       Impact factor: 4.249

Review 7.  To (TGF)beta or not to (TGF)beta: fine-tuning of Smad signaling via post-translational modifications.

Authors:  Katharine H Wrighton; Xin-Hua Feng
Journal:  Cell Signal       Date:  2008-02-15       Impact factor: 4.315

8.  Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7.

Authors:  Manasi N Shukla; Jane L Rose; Rabindranath Ray; Kira L Lathrop; Anuradha Ray; Prabir Ray
Journal:  Am J Respir Cell Mol Biol       Date:  2008-11-06       Impact factor: 6.914

9.  Transforming growth factor-{beta}-inducible phosphorylation of Smad3.

Authors:  Guannan Wang; Isao Matsuura; Dongming He; Fang Liu
Journal:  J Biol Chem       Date:  2009-02-13       Impact factor: 5.157

10.  Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.

Authors:  A R Garcia-Rendueles; J S Rodrigues; M E R Garcia-Rendueles; M Suarez-Fariña; S Perez-Romero; F Barreiro; I Bernabeu; J Rodriguez-Garcia; L Fugazzola; T Sakai; F Liu; J Cameselle-Teijeiro; S B Bravo; C V Alvarez
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.